Autoimmune Neutropenia in Multiple Myeloma and the Role of Clonal T-Cell Expansion: Evidence of Cross-Talk Between B-Cell and T-Cell Lineages?
Autoimmune Neutropenia in Multiple Myeloma and the Role of Clonal T-Cell Expansion: Evidence of Cross-Talk Between B-Cell and T-Cell Lineages? Clin Lymphoma Myeloma Leuk. 2013 Oct 29; Authors: Aryal MR, Bhatt VR, Tandra P, Krishnamurthy J, Yuan J, Greiner TC, Akhtari M PMID: 24183500 [PubMed - as supplied by publisher]
First-line imatinib can achieve similar efficacy as first-line nilotinib after standardized management according to the ELN recommendations. Treatment based on imatinib as first-line treatment, then switching to nilotinib after standardized management is feasible and effective. Both nilotinib and imatinib are well tolerated and safe.
The value of PET/CT in the staging and assessment of treatment response in marginal zone lymphoma (MZL) lymphomas remains controversial. We investigated radiological characteristics of subcutaneous MZL, as seen on PET/CT scans.
ConclusionPlerixafor proved effective to mobilize adequate numbers of PBSCs in individual patients with relapsed malignancies after prior single or tandem HDC+PBSCT. These PBSCs could establish sustained multi-lineage hematopoietic engraftment without any sequelae.
The objective of this pharmacogenetic study was to investigate the relationship of methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms with methotrexate (MTX) induced toxicities and plasma homocysteine level in Acute Lymphoblastic Leukemia (ALL) patients of Bangladesh. Several polymorphisms result in reduced MTHFR activity that causes impaired remethylation of homocysteine to methionine and abnormal MTX metabolism especially in tissues with high turnover. Therefore, the risk of elevated plasma homocysteine as well as MTX induced toxicities become higher with MTHFR polymorphisms.Patients and MethodsWe recruited 1...
MicroAbstract: Plerixafor, a stem cell mobilizer with proven potential to rescue "poorly" mobilizing patients, was applied after salvage chemotherapy (+G-CSF) in a limited series of patients with potentially curable malignancies, who had relapsed after a previous autograft. This led to successful stem cell mobilization in all patients, who experienced sustained engraftment after further high-dose chemotherapy supported by the plerixafor-mobilized stem cells.
The present study investigated the effect of MTHFR C677T and A1298C polymorphisms on methotrexate (MTX) induced toxicities and increased plasma homocysteine level in Acute Lymphoblastic Leukemia (ALL) patients for the first time in Bangladesh. MTX induced mucositis and diarrhea are found to be significantly associated with MTHFR C677T and MTHFR A1298C polymorphisms. In addition, the risk of elevated plasma homocysteine level was 5 to 6 times higher for both polymorphisms.
Authors: Bouchla A, Thomopoulos T, Papageorgiou S, Tsirigotis P, Bazani E, Gkirkas K, Vasilatou D, Glezou E, Stavroulaki G, Gkontopoulos K, Dimitriadis G, Pappa V Abstract The coexistence of a myeloid and a lymphoid neoplasm in the same patient is a rare finding. We retrospectively searched the records of the Hematology Division of the Second Department of Internal Medicine and Research Institute at Attikon University General Hospital of Athens from 2003 to 2018. Nine cases have been identified in a total of 244 BCR-/ABL1- negative MPN and 25 MDS/MPN patients and 1062 LPD patients referred to our institution betwee...
ConclusionChemotherapy followed by ASCT using a conditioning regimen of reduced melphalan and pharmacokinetically targeted busulfan is a promising strategy for treating patients with relapsed or refractory DLBCL who also have end-stage renal disease and are receiving hemodialysis.